227 related articles for article (PubMed ID: 20847297)
1. Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity.
Kim KH; Lee GY; Kim JI; Ham M; Won Lee J; Kim JB
J Lipid Res; 2010 Dec; 51(12):3425-33. PubMed ID: 20847297
[TBL] [Abstract][Full Text] [Related]
2. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
[TBL] [Abstract][Full Text] [Related]
3. Liver X receptors inhibit macrophage proliferation through downregulation of cyclins D1 and B1 and cyclin-dependent kinases 2 and 4.
Pascual-García M; Carbó JM; León T; Matalonga J; Out R; Van Berkel T; Sarrias MR; Lozano F; Celada A; Valledor AF
J Immunol; 2011 Apr; 186(8):4656-67. PubMed ID: 21398609
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.
Lee JM; Gang GT; Kim DK; Kim YD; Koo SH; Lee CH; Choi HS
J Biol Chem; 2014 Jan; 289(2):1079-91. PubMed ID: 24265317
[TBL] [Abstract][Full Text] [Related]
5. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα.
Ducheix S; Podechard N; Lasserre F; Polizzi A; Pommier A; Murzilli S; Di Lisio C; D'Amore S; Bertrand-Michel J; Montagner A; Pineau T; Loiseau N; Lobaccaro JM; Martin PG; Guillou H
Biochimie; 2013 Mar; 95(3):556-67. PubMed ID: 23063693
[TBL] [Abstract][Full Text] [Related]
6. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries.
Blaschke F; Leppanen O; Takata Y; Caglayan E; Liu J; Fishbein MC; Kappert K; Nakayama KI; Collins AR; Fleck E; Hsueh WA; Law RE; Bruemmer D
Circ Res; 2004 Dec; 95(12):e110-23. PubMed ID: 15539633
[TBL] [Abstract][Full Text] [Related]
7. Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling.
Ogihara T; Chuang JC; Vestermark GL; Garmey JC; Ketchum RJ; Huang X; Brayman KL; Thorner MO; Repa JJ; Mirmira RG; Evans-Molina C
J Biol Chem; 2010 Feb; 285(8):5392-404. PubMed ID: 20007976
[TBL] [Abstract][Full Text] [Related]
8. Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Lee TY; Chang PL; Chen WT; Juang HH
Prostate; 2015 May; 75(6):603-15. PubMed ID: 25560459
[TBL] [Abstract][Full Text] [Related]
9. LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effects.
Spillmann F; Van Linthout S; Miteva K; Lorenz M; Stangl V; Schultheiss HP; Tschöpe C
Atherosclerosis; 2014 Jan; 232(1):1-9. PubMed ID: 24401210
[TBL] [Abstract][Full Text] [Related]
10. A role for protein inhibitor of activated STAT1 (PIAS1) in lipogenic regulation through SUMOylation-independent suppression of liver X receptors.
Zhang Y; Gan Z; Huang P; Zhou L; Mao T; Shao M; Jiang X; Chen Y; Ying H; Cao M; Li J; Li J; Zhang WJ; Yang L; Liu Y
J Biol Chem; 2012 Nov; 287(45):37973-85. PubMed ID: 22969086
[TBL] [Abstract][Full Text] [Related]
11. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.
Noghero A; Perino A; Seano G; Saglio E; Lo Sasso G; Veglio F; Primo L; Hirsch E; Bussolino F; Morello F
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2280-8. PubMed ID: 22723445
[TBL] [Abstract][Full Text] [Related]
12. Liver X receptor agonists decrease ENaC-mediated sodium transport in collecting duct cells.
Soodvilai S; Jia Z; Fongsupa S; Chatsudthipong V; Yang T
Am J Physiol Renal Physiol; 2012 Dec; 303(12):F1610-6. PubMed ID: 23077096
[TBL] [Abstract][Full Text] [Related]
13. Liver X receptor activation inhibits osteoclastogenesis by suppressing NF-κB activity and c-Fos induction and prevents inflammatory bone loss in mice.
Kim HJ; Yoon KA; Yoon HJ; Hong JM; Lee MJ; Lee IK; Kim SY
J Leukoc Biol; 2013 Jul; 94(1):99-107. PubMed ID: 23657115
[TBL] [Abstract][Full Text] [Related]
14. Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
Bełtowski J
Cardiovasc Ther; 2008; 26(4):297-316. PubMed ID: 19035881
[TBL] [Abstract][Full Text] [Related]
15. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor.
Blaschke F; Takata Y; Caglayan E; Collins A; Tontonoz P; Hsueh WA; Tangirala RK
Circ Res; 2006 Dec; 99(12):e88-99. PubMed ID: 17110595
[TBL] [Abstract][Full Text] [Related]
16. ABCA1 upregulating apolipoproein M expression mediates via the RXR/LXR pathway in HepG2 cells.
Di D; Wang Z; Liu Y; Luo G; Shi Y; Berggren-Söderlund M; Nilsson-Ehle P; Zhang X; Xu N
Biochem Biophys Res Commun; 2012 Apr; 421(1):152-6. PubMed ID: 22516753
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
[TBL] [Abstract][Full Text] [Related]
18. Liver X receptor activation inhibits SGLT2-mediated glucose transport in human renal proximal tubular cells.
Chonlaket P; Wongwan T; Soodvilai S
Exp Physiol; 2018 Feb; 103(2):250-260. PubMed ID: 29127736
[TBL] [Abstract][Full Text] [Related]
19. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms.
Morello F; Saglio E; Noghero A; Schiavone D; Williams TA; Verhovez A; Bussolino F; Veglio F; Mulatero P
Atherosclerosis; 2009 Nov; 207(1):38-44. PubMed ID: 19426978
[TBL] [Abstract][Full Text] [Related]
20. Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1.
Briand O; Touche V; Colin S; Brufau G; Davalos A; Schonewille M; Bovenga F; Carrière V; de Boer JF; Dugardin C; Riveau B; Clavey V; Tailleux A; Moschetta A; Lasunción MA; Groen AK; Staels B; Lestavel S
Gastroenterology; 2016 Mar; 150(3):650-8. PubMed ID: 26602218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
